Ocuflox®
Ofloxacin 0.3% · ophthalmic solution
Antibiotic
Approved uses
Bacterial conjunctivitis
1 or 2 drops q2h to q4h on days 1 and 2, then 1 or 2 drops QID on days 3 through 7.
Bacterial corneal ulcer
Days 1 and 2: 1 or 2 drops q30min while awake, plus 1 or 2 drops on waking at about 4 and 6 hours after retiring. Days 3 through 7 to 9: 1 or 2 drops hourly while awake. Days 7 to 9 through completion: 1 or 2 drops QID.
Contraindications
History of hypersensitivity to ofloxacin, to other quinolones, or to any component of the formulation.
5 mL in a 10 mL dropper bottle, 0.3% solution, 3 mg ofloxacin per mL
Fluoroquinolone; bactericidal at concentrations equal to or slightly above inhibitory concentrations, thought to act by inhibiting DNA gyrase, the bacterial enzyme catalyzing duplication, transcription and repair of DNA. In vitro activity covers a broad range of gram-positive and gram-negative aerobes and anaerobes; cross-resistance occurs with other fluoroquinolones but generally not with beta-lactams or aminoglycosides.
Warnings & Precautions
- Not for injection: Do not inject subconjunctivally or introduce directly into the anterior chamber of the eye.
- Hypersensitivity reactions: Rare anaphylactic reaction/shock and fatal hypersensitivity reactions have been reported with systemic quinolones, including ofloxacin, some after the first dose; some were accompanied by cardiovascular collapse, loss of consciousness, angioedema, airway obstruction, dyspnea, urticaria, and itching. Discontinue if an allergic reaction occurs; serious acute reactions may require immediate emergency treatment, with oxygen and airway management, including intubation, as indicated.
- Stevens-Johnson syndrome: One report of Stevens-Johnson syndrome progressing to toxic epidermal necrolysis during topical ophthalmic use; discontinue at the first appearance of skin rash or any other sign of hypersensitivity.
- Overgrowth of nonsusceptible organisms: Prolonged use may result in overgrowth of nonsusceptible organisms including fungi; if superinfection occurs, discontinue and start alternative therapy, and whenever clinical judgment dictates, examine with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining.
- Arthropathy in immature animals: Systemic quinolones, including ofloxacin, have led to lesions or erosions of the cartilage in weight-bearing joints and other signs of arthropathy in immature animals of various species; systemic ofloxacin at 10 mg/kg/day in young dogs (110 times the maximum recommended daily adult ophthalmic dose) has been associated with these effects.
- Drug interactions: Specific drug interaction studies have not been conducted with the ophthalmic solution, but systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
Common Side Effects
The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort. Other reported reactions include stinging, redness, itching, chemical conjunctivitis or keratitis, ocular, periocular or facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain. Rare reports of dizziness and nausea have been received.
Pregnancy: No adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential risk to the fetus. Ofloxacin has not been shown to be teratogenic at doses as high as 810 mg/kg/day in rats and 160 mg/kg/day in rabbits; those doses, 9000 times and 1800 times the maximum recommended daily ophthalmic dose, were embryocidal (decreased fetal body weight in rats, increased fetal mortality in rabbits), and minor fetal skeletal variations were reported in rats at 810 mg/kg/day. Rat dosing up to 360 mg/kg/day in late gestation did not affect late fetal development, labor, delivery, lactation, neonatal viability or growth of the newborn.
Lactation: A single 200 mg oral dose in nursing women produced milk concentrations similar to plasma; excretion in human milk after topical ophthalmic dosing is unknown. Because of the potential for serious adverse reactions in nursing infants, decide whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness not established below 1 year of age.